Mesfin FB, Al-Dhahir MA (2022) Gliomas. In: StatPearls. StatPearls Publishing, Treasure Island (FL)

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostrom QT, Gittleman H, Liao P et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158

Article  PubMed  PubMed Central  Google Scholar 

Velnar T, Smrdel U, Popovic M, Bunc G (2010) Genetic markers in oligodendroglial tumours. Radiol Oncol 44:13–18. https://doi.org/10.2478/v10019-010-0007-y

Article  PubMed  PubMed Central  Google Scholar 

Mørk SJ, Lindegaard KF, Halvorsen TB et al (1985) Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63:881–889. https://doi.org/10.3171/jns.1985.63.6.0881

Article  PubMed  Google Scholar 

Van den Bent MJ, Reni M, Gatta G, Vecht C (2008) Oligodendroglioma. Crit Rev Oncol Hematol 66:262–272. https://doi.org/10.1016/j.critrevonc.2007.11.007

Article  PubMed  Google Scholar 

Iwadate Y, Matsutani T, Hara A et al (2019) Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol 141:205–211. https://doi.org/10.1007/s11060-018-03027-5

Article  CAS  PubMed  Google Scholar 

Chung C, Laperriere N (2015) Radiation therapy and grade II/III oligodendroglial tumors. CNS Oncol 4:325–332. https://doi.org/10.2217/cns.15.25

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okita Y, Narita Y, Miyakita Y et al (2012) IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol 41:1325–1336. https://doi.org/10.3892/ijo.2012.1564

Article  CAS  PubMed  Google Scholar 

van den Bent MJ, Chinot O, Boogerd W et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC brain tumor group phase II study 26972. Ann Oncol 14:599–602. https://doi.org/10.1093/annonc/mdg157

Article  PubMed  Google Scholar 

Triebels VHJM, Taphoorn MJB, Brandes AA et al (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63:904–906. https://doi.org/10.1212/01.wnl.0000137049.65631.db

Article  CAS  PubMed  Google Scholar 

Kumar A, Boyle EA, Tokita M et al (2014) Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol 15:530. https://doi.org/10.1186/s13059-014-0530-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe T, Yokoo H, Yokoo M et al (2001) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60:1181–1189. https://doi.org/10.1093/jnen/60.12.1181

Article  CAS  PubMed  Google Scholar 

Hoang-Xuan K, He J, Huguet S et al (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57:1278–1281. https://doi.org/10.1212/wnl.57.7.1278

Article  CAS  PubMed  Google Scholar 

Ritland SR, Ganju V, Jenkins RB (1995) Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 12:277–282. https://doi.org/10.1002/gcc.2870120407

Article  CAS  PubMed  Google Scholar 

Jothi J, Janardhanam VA, Krishnaswamy R (2020) Metabolic variations between low-grade and high-grade gliomas-profiling by 1H NMR spectroscopy. J Proteome Res 19:2483–2490. https://doi.org/10.1021/acs.jproteome.0c00243

Article  CAS  PubMed  Google Scholar 

Zhao H, Heimberger AB, Lu Z et al (2016) Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget 7:20486–20495. https://doi.org/10.18632/oncotarget.7974

Article  PubMed  PubMed Central  Google Scholar 

Rijpkema M, Schuuring J, van der Meulen Y et al (2003) Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 16:12–18. https://doi.org/10.1002/nbm.807

Article  CAS  PubMed  Google Scholar 

Chawla S, Oleaga L, Wang S et al (2010) Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging 20:3–8. https://doi.org/10.1111/j.1552-6569.2008.00307.x

Article  PubMed  Google Scholar 

Naveed MA, Goyal P, Malhotra A et al (2018) Grading of oligodendroglial tumors of the brain with apparent diffusion coefficient, magnetic resonance spectroscopy, and dynamic susceptibility contrast imaging. Neuroradiol J 31:379–385. https://doi.org/10.1177/1971400918757217

Article  PubMed  PubMed Central  Google Scholar 

Patel AP, Tirosh I, Trombetta JJ et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401. https://doi.org/10.1126/science.1254257

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pang B, Xu J, Hu J et al (2019) Single-cell RNA-seq reveals the invasive trajectory and molecular cascades underlying glioblastoma progression. Mol Oncol 13:2588–2603. https://doi.org/10.1002/1878-0261.12569

Article  CAS  PubMed  PubMed Central  Google Scholar 

Darmanis S, Sloan SA, Croote D et al (2017) Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep 21:1399–1410. https://doi.org/10.1016/j.celrep.2017.10.030

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiong Z, Yang Q, Li X (2020) Effect of intra- and inter-tumoral heterogeneity on molecular characteristics of primary IDH-wild type glioblastoma revealed by single-cell analysis. CNS Neurosci Ther 26:981–989. https://doi.org/10.1111/cns.13396

Article  CAS  PubMed  PubMed Central  Google Scholar 

Comba A, Faisal SM, Varela ML et al (2021) Uncovering spatiotemporal heterogeneity of high-grade gliomas: from disease biology to therapeutic implications. Front Oncol 11:703764. https://doi.org/10.3389/fonc.2021.703764

Article  PubMed  PubMed Central  Google Scholar 

Yu K, Hu Y, Wu F et al (2020) Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies. Natl Sci Rev 7:1306–1318. https://doi.org/10.1093/nsr/nwaa099

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tirosh I, Venteicher AS, Hebert C et al (2016) Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 539:309–313. https://doi.org/10.1038/nature20123

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Maaten L, Hinton G (2008) Visualizing data using t-SNE. J Mach Learn Res 9:2579–2605

Google Scholar 

Rtsne: T-distributed stochastic neighbor embedding using a barnes-hut implementation version 0.15 from CRAN. https://rdrr.io/cran/Rtsne/. Accessed 21 Jan 2022

Lun ATL, Bach K, Marioni JC (2016) Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol 17:75. https://doi.org/10.1186/s13059-016-0947-7

Article  CAS  PubMed  Google Scholar 

Xiao Z, Dai Z, Locasale JW (2019) Metabolic landscape of the tumor microenvironment at single cell resolution. Nat Commun 10:3763. https://doi.org/10.1038/s41467-019-11738-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allam A, Radwi A, El Weshi A, Hassounah M (2000) Oligodendroglioma: an analysis of prognostic factors and treatment results. Am J Clin Oncol 23:170–175

Article  CAS  PubMed  Google Scholar 

Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60:443–456. https://doi.org/10.1016/S0090-3019(03)00167-8

Article  PubMed  Google Scholar 

Jaeckle KA, Ballman KV, Rao RD et al (2006) Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. JCO 24:1246–1252. https://doi.org/10.1200/JCO.2005.04.9874

Article  CAS  Google Scholar 

Chinot O, Barrié M, Cournède A et al (2005) Phase II study of temozolomide (TMZ) administered on a 7 days on-7 days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM). JCO 23:1523–1523. https://doi.org/10.1200/jco.2005.23.16_suppl.1523

Article  Google Scholar 

Seth Nanda C, Venkateswaran SV, Patani N, Yuneva M (2020) Defining a metabolic landscape of tumours: genome meets metabolism. Br J Cancer 122:136–149. https://doi.org/10.1038/s41416-019-0663-7

Article  CAS  PubMed  Google Scholar 

Reznik E, Luna A, Aksoy BA et al (2018) A landscape of metabolic variation across tumor types. Cell Syst 6:301-313.e3. https://doi.org/10.1016/j.cels.2017.12.014

Article  CAS  PubMed  PubMed Central